The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of
alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates
of about 30% of individuals in the United States. A subset of these will develop progressive
disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis
and liver failure. We hypothesize that LUM-201 (Ibutamoren mesylate) will decrease
intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy
(1H-MRS).